Logo image of ORIC

ORIC PHARMACEUTICALS INC (ORIC) Stock Fundamental Analysis

NASDAQ:ORIC - Nasdaq - US68622P1093 - Common Stock - Currency: USD

9.85  -1.38 (-12.29%)

After market: 9.9 +0.05 (+0.51%)

Fundamental Rating

3

Overall ORIC gets a fundamental rating of 3 out of 10. We evaluated ORIC against 572 industry peers in the Biotechnology industry. While ORIC has a great health rating, there are worries on its profitability. ORIC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ORIC has reported negative net income.
In the past year ORIC has reported a negative cash flow from operations.
In the past 5 years ORIC always reported negative net income.
In the past 5 years ORIC always reported negative operating cash flow.
ORIC Yearly Net Income VS EBIT VS OCF VS FCFORIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

ORIC has a Return On Assets (-39.68%) which is comparable to the rest of the industry.
ORIC's Return On Equity of -43.75% is fine compared to the rest of the industry. ORIC outperforms 69.38% of its industry peers.
Industry RankSector Rank
ROA -39.68%
ROE -43.75%
ROIC N/A
ROA(3y)-34.12%
ROA(5y)-31.12%
ROE(3y)-37.95%
ROE(5y)-33.96%
ROIC(3y)N/A
ROIC(5y)N/A
ORIC Yearly ROA, ROE, ROICORIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -10 -20 -30 -40

1.3 Margins

ORIC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORIC Yearly Profit, Operating, Gross MarginsORIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ORIC has been increased compared to 1 year ago.
ORIC has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ORIC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ORIC Yearly Shares OutstandingORIC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
ORIC Yearly Total Debt VS Total AssetsORIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 14.05 indicates that ORIC is not in any danger for bankruptcy at the moment.
ORIC has a better Altman-Z score (14.05) than 89.38% of its industry peers.
There is no outstanding debt for ORIC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.05
ROIC/WACCN/A
WACCN/A
ORIC Yearly LT Debt VS Equity VS FCFORIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

ORIC has a Current Ratio of 13.15. This indicates that ORIC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 13.15, ORIC belongs to the top of the industry, outperforming 86.19% of the companies in the same industry.
ORIC has a Quick Ratio of 13.15. This indicates that ORIC is financially healthy and has no problem in meeting its short term obligations.
ORIC's Quick ratio of 13.15 is amongst the best of the industry. ORIC outperforms 86.37% of its industry peers.
Industry RankSector Rank
Current Ratio 13.15
Quick Ratio 13.15
ORIC Yearly Current Assets VS Current LiabilitesORIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

ORIC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.55%, which is quite good.
EPS 1Y (TTM)9.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ORIC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.99% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.71%
EPS Next 2Y-3.66%
EPS Next 3Y-1.51%
EPS Next 5Y9.99%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORIC Yearly Revenue VS EstimatesORIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ORIC Yearly EPS VS EstimatesORIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ORIC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ORIC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ORIC Price Earnings VS Forward Price EarningsORIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORIC Per share dataORIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.66%
EPS Next 3Y-1.51%

More info and screens

0

5. Dividend

5.1 Amount

ORIC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORIC PHARMACEUTICALS INC

NASDAQ:ORIC (2/11/2025, 8:00:01 PM)

After market: 9.9 +0.05 (+0.51%)

9.85

-1.38 (-12.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners92.75%
Inst Owner Change-41.77%
Ins Owners1.54%
Ins Owner Change0.66%
Market Cap695.11M
Analysts88.89
Price Target19.1 (93.91%)
Short Float %17.62%
Short Ratio20.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3.73%
Min EPS beat(2)-7.05%
Max EPS beat(2)-0.41%
EPS beat(4)2
Avg EPS beat(4)2.65%
Min EPS beat(4)-7.05%
Max EPS beat(4)16.82%
EPS beat(8)6
Avg EPS beat(8)4.98%
EPS beat(12)7
Avg EPS beat(12)3.54%
EPS beat(16)9
Avg EPS beat(16)-1.19%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.12%
EPS NQ rev (1m)-0.44%
EPS NQ rev (3m)-10.96%
EPS NY rev (1m)0.01%
EPS NY rev (3m)-2.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.54
P/tB 2.54
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-2.11
Fwd EYN/A
FCF(TTM)-1.56
FCFYN/A
OCF(TTM)-1.54
OCFYN/A
SpS0
BVpS3.88
TBVpS3.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.68%
ROE -43.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.12%
ROA(5y)-31.12%
ROE(3y)-37.95%
ROE(5y)-33.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.15
Quick Ratio 13.15
Altman-Z 14.05
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)133.72%
Cap/Depr(5y)109%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.36%
EPS Next Y4.71%
EPS Next 2Y-3.66%
EPS Next 3Y-1.51%
EPS Next 5Y9.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.41%
EBIT Next 3Y-7.39%
EBIT Next 5YN/A
FCF growth 1Y-40.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.09%
OCF growth 3YN/A
OCF growth 5YN/A